News

The Pharma Letter2h
AstraZeneca gets EU approval for Imfinzi combo in early bladder cancer
British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...
AstraZeneca considers moving listing to US, the Times reports
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
Why AstraZeneca Stock Got Thumped on Thursday
A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...
AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment
AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...
AstraZeneca's Imfinzi gets EU green light
Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative ...
AstraZeneca CEO Wants to Move Listing to US, Times Reports
AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...
AstraZeneca exit: here’s what it really means for the UK
AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...
AstraZeneca's Imfinzi receives EU approval, AFC Energy launches Joint venture with ICG
OPEN The FTSE 100 was expected to open 19.9 points lower on Friday after wrapping up the previous session 0.55% higher at 8,823.20.